Try our mobile app

Press Release: Completed XTEND-Kids Phase 3 study strengthens potential of ALTUVIIIOTM to redefine expectations for treatment of children <12 years of age with hemophilia A

Published: 2023-03-02 07:00:00 ET
<<<  go to SNY company page

Completed XTEND-Kids Phase 3 studystrengthenspotential of ALTUVIIIO™toredefineexpectationsfor treatment ofchildren